Literature DB >> 26316167

Inhibition of CD147 expression by RNA interference reduces proliferation, invasion and increases chemosensitivity in cancer stem cell-like HT-29 cells.

Jie Chen1, Yuqin Pan2, Bangshun He2, Houqun Ying2, Feng Wang2, Huiling Sun1, Qiwen Deng2, Xian Liu2, Kang Lin2, Hongxin Peng2, William C Cho3, Shukui Wang2.   

Abstract

The association between CD147 and cancer stem cells (CSCs) provides a new angle for cancer treatments. The aim of this study was to investigate the biological roles of CD147 in colorectal CSCs. The Oct4-green fluorescent protein (GFP) vector was used to isolate CSCs and pYr-mir30-shRNA was used to generate short hairpin RNA (shRNA) specifically for CD147. After RNA interference (RNAi), CD147 was evaluated by reverse transcription‑quantitative PCR and western blot analysis, and its biological functions were assessed by MTT and invasion assays. The results showed that the differentiation of isolated CSC-like HT-29 cells was blocked and these cells were highly positive for CD44 and CD147. RNAi-mediated CD147 silencing reduced the expression of CD147 at both mRNA and protein levels. Moreover, the activities of proliferation and invasion were decreased obviously in CSCs. Knockdown of CD147 increased the chemosensitivity of CSC-like cells to gemcitabine, cisplatin, docetaxel at 0.1, 1 and 10 µM respectively, however, there was no significant difference among the three groups to paclitaxel at 10 µM. In conclusion, these results suggest that CD147 plays an important role in colorectal CSCs and might be regarded as a novel CSC-specific targeted strategy against colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26316167     DOI: 10.3892/ijo.2015.3138

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  4 in total

1.  Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surface.

Authors:  Xiaoying Ye; King C Chan; Andrew M Waters; Matthew Bess; Adam Harned; Bih-Rong Wei; Jadranka Loncarek; Brian T Luke; Benjamin C Orsburn; Bradley D Hollinger; Robert M Stephens; Rachel Bagni; Alex Martinko; James A Wells; Dwight V Nissley; Frank McCormick; Gordon Whiteley; Josip Blonder
Journal:  Oncotarget       Date:  2016-12-27

Review 2.  Cyclophilin A/CD147 Interaction: A Promising Target for Anticancer Therapy.

Authors:  Jang Mi Han; Hye Jin Jung
Journal:  Int J Mol Sci       Date:  2022-08-19       Impact factor: 6.208

Review 3.  Drug resistance related to aberrant glycosylation in colorectal cancer.

Authors:  Ninon Very; Tony Lefebvre; Ikram El Yazidi-Belkoura
Journal:  Oncotarget       Date:  2017-11-03

4.  CD147 Promotes Cell Small Extracellular Vesicles Release during Colon Cancer Stem Cells Differentiation and Triggers Cellular Changes in Recipient Cells.

Authors:  Donatella Lucchetti; Filomena Colella; Luigi Perelli; Claudio Ricciardi-Tenore; Federica Calapà; Micol E Fiori; Federica Carbone; Ruggero De Maria; Alessandro Sgambato
Journal:  Cancers (Basel)       Date:  2020-01-21       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.